Gastrointestinal cancers, particularly stomach and colorectal cancer, are on the rise worldwide. Early-stage cancers often remain asymptomatic for years, leading to delayed diagnoses and poor patient outcomes. The need for AI-powered early detection and continuous monitoring systems has never been greater.

Key Risk Factors Driving Cancer Growth

• Helicobacter pylori infection increases the risk of stomach cancer by 2 to 6 times.

• Chronic gastric inflammation leads to a 6-fold increase in atrophic gastritis, progressing to 10-20 times higher cancer risk.

• Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, significantly raises the risk of colorectal cancer (up to 7 times higher in severe cases).

• 80-85% of colorectal cancer cases originate from precancerous polyps, making early detection critical.

Gastrointestinal Cancer Statistics

United States

• Colorectal cancer (15.7%) is the second leading cause of cancer-related deaths in the U.S.

• Stomach cancer (4%) is a growing concern, though less common than colorectal cancer.

• Digestive cancers make up 19.7% of all cancer cases in the U.S., ranking third among cancer categories. (Source: 2022 American Cancer Society)

Global Trends

• Colorectal cancer (9.6%) is among the top 3 most common cancers worldwide.

• Stomach cancer (4.9%) is prevalent in high-risk regions like East Asia, Europe, and Latin America.

• Digestive cancers account for 14.5% of all cancer cases globally, making them the #1 category of cancer incidence worldwide. (Source: 2024 WHO Report)

The Only AI Solution for Comprehensive Gastrointestinal Cancer Screening

Apex AI stands out as the only global AI-powered diagnostic system capable of analyzing both stomach and colorectal cancer at an advanced Level 3 grading system. Unlike competitors, Apex AI provides detailed disease classification and risk stratification, making it a leader in AI-driven gastrointestinal diagnostics.

How Apex AI Compares to Competitors

Why Apex AI is Superior

• Only AI system capable of full gastrointestinal lesion classification

• Advanced AI grading system differentiates between inflammation, ulcers, polyps, early-stage, and advanced cancer

• Applies to both stomach and colorectal cancer detection, whereas most competitors focus on a single organ

Key Advantages of Apex AI’s Solution

1. Broad Disease Detection

• Competing AI models mostly differentiate between normal and abnormal tissue.

• Apex AI detects the full cancer development process, from precancerous lesions to advanced cancer.

• Covers both stomach and colorectal regions, while most competitors specialize in only one.

2. Disease Progression Tracking

• Provides longitudinal disease tracking, allowing physicians to monitor lesion evolution over time.

• Enhances treatment planning and patient lifestyle recommendations based on risk assessment.

3. Unmatched Diagnostic Accuracy

• Apex AI achieves 95% accuracy for stomach cancer and 98% accuracy for colorectal cancer.

• This surpasses competing AI models, which typically lack large-scale datasets and detailed lesion classification.

4. Future Expansion: AI-Driven Dietary Management

• Apex AI is developing AI-powered dietary analysis to enhance digestive health monitoring.

• Future integration will provide dietary recommendations for cancer prevention and treatment.

Technological Superiority: Why Apex AI Leads in AI-Powered Diagnostics

1. Five Years of AI Algorithm Refinement

• Continuous optimization has led to superior performance, with stomach cancer detection reaching 95% accuracy and colorectal cancer detection achieving 98% accuracy.

2. World’s Largest Gastrointestinal Endoscopy AI Dataset

• Trained on over 1 million endoscopic images, making it the most comprehensive AI system for gastrointestinal cancer.

• Overcomes biases found in small-scale datasets, ensuring robust AI predictions.

3. Multi-Modal AI Data Fusion

• Integrates endoscopic imaging with numerical health data, improving AI-driven clinical decision-making.

• Fusion of visual and statistical data enhances diagnostic precision and reliability.

Apex AI: Leading the Future of AI-Powered Gastrointestinal Cancer Detection

With superior lesion classification, unmatched accuracy, and long-term disease tracking, Apex AI is redefining cancer diagnostics. Our mission is to provide AI-powered, life-saving early detection for patients worldwide.

With the growing burden of digestive cancers, the market for AI-powered endoscopy and cancer detection solutions is rapidly expanding.

Global Market Size for Gastrointestinal Diagnostics

• Total GI diagnostic & treatment market: $2.1 trillion

  • Stomach cancer: $1.5 trillion

  • Colorectal cancer: $305 billion

  • Esophageal and other GI cancers: $285 billion

• Endoscopic Imaging Market

  • Global endoscopic screening market: $1.2 trillion (U.S., China, Japan, Europe, Korea)

  • U.S. endoscopic screening market: $700 billion

AI-Powered Diagnostic Market

• U.S. AI-assisted endoscopic image interpretation market: $66 billion (Assuming a 10% AI adoption rate in the endoscopy market)

• Global AI-driven GI diagnostics market: Projected multi-billion-dollar opportunity

Apex AI’s Vision

Apex AI aims to redefine early cancer detection by leveraging AI to analyze endoscopic images, predict cancer risks, and track disease progression in real time. Our mission is to increase survival rates and optimize clinical workflows by providing AI-assisted precision diagnostics for gastroenterologists worldwide.

With the rapid growth of AI adoption in healthcare, Apex AI is positioned to be a leader in the future of AI-driven cancer diagnostics.

Apex AI has a three-stage international expansion plan focusing on Korea, the U.S., and Japan, followed by a broader global rollout.

2025-26: Domestic Market Expansion (South Korea)

• Clinical validation with major hospitals, including:

  • Seoul National University Bundang Hospital

  • Inha University Hospital

  • Hanlim University Sacred Heart Hospital

• Initial rollout in health screening centers with direct sales and platform partnerships.

• AI-powered digestive health monitoring collaboration with Next Biomed & iKooB.

2025-26: Entry into the U.S. Market

• Pilot program in Utah (Phase 2 region) before expanding to key medical hubs like New York, California, Boston, and Texas.

• Strategic collaborations with top-tier U.S. institutions, including:

  • Harvard Medical School (MGH) – Two professors onboarding as advisors.

  • Oracle Healthcare – AI integration partnerships.

  • Medtronic – Exploring collaboration on medical AI devices.

• Investment network expansion – Attracting U.S.-based investors to establish a sustainable market presence.

Japan Expansion

• AI licensing to endoscopy manufacturers, including Olympus, Pentax, and Fujifilm.

• Partnership with CEC (Fujitsu subsidiary) to penetrate Japanese medical institutions.

• Regulatory alignment for market approval and expansion into hospitals & screening centers.

Post-2027: Global Expansion

• Following successful market entries in Korea, the U.S., and Japan, Apex AI will scale into Europe, China, and other high-demand regions.

• Cloud-based AI diagnostics will drive accessibility, making Apex AI a global leader in AI-powered gastrointestinal cancer detection.

Challenges in Early Gastrointestinal Cancer Detection

Despite advancements in medical imaging and endoscopy, early detection of stomach and colorectal cancer remains a major challenge due to limitations in current diagnostic methods.

Key Limitations of Current Gastrointestinal Cancer Diagnostics

• High Error Rate in Endoscopic Interpretation

  • 33.6% misdiagnosis rate in gastrointestinal endoscopic evaluations.

  • Many early-stage abnormalities go undetected due to the complexity of lesions and human error.

• Long Asymptomatic Periods

  • Gastrointestinal cancers remain asymptomatic for up to 10 years, delaying diagnosis.

  • By the time symptoms appear, cancer is often in an advanced stage with poor survival rates.

• Low Survival Rates for Late-Stage Diagnosis

  • If early detection fails, stomach and colorectal cancer survival rates drop to 20-40%.

  • Late detection leads to increased treatment costs, reduced quality of life, and higher mortality.

AI-Powered Solutions by Apex AI

Artificial intelligence can revolutionize early cancer detection by enhancing endoscopic interpretation, reducing diagnostic errors, and enabling proactive cancer monitoring.

How AI Solves These Challenges

• AI-Driven Endoscopic Analysis with 90%+ Accuracy

  • Machine learning models improve endoscopic imaging interpretation, significantly reducing false negatives and misdiagnoses.

  • Real-time AI assistance helps doctors detect subtle, early-stage abnormalities more effectively.

• Continuous Monitoring and Risk Prediction

  • AI enables longitudinal tracking of precancerous lesions, identifying high-risk patients before cancer develops.

  • This proactive approach reduces the 10-year diagnostic delay, allowing earlier interventions.

• Drastically Improved Survival Rates with Early Diagnosis

  • Stomach cancer: 96.9% survival rate with early detection.

  • Colorectal cancer: 93.8% survival rate with early detection.

  • AI-powered screening helps ensure timely and life-saving interventions.

Why AI is the Future of Cancer Diagnostics

By integrating AI into gastrointestinal cancer screening, Apex AI aims to bridge the gap between medical imaging limitations and real-world clinical needs. Our AI-driven endoscopic analysis platform has the potential to become a standard tool in global cancer prevention, improving survival rates, reducing costs, and optimizing patient outcomes.

Apex AI has been at the forefront of AI-powered gastrointestinal cancer diagnostics, continuously innovating and expanding through strategic partnerships, R&D breakthroughs, and global commercialization efforts.

2024

• Selected for the “TIPS Global Marketing Support Program” (Korea Ministry of SMEs & Startups).

• Chosen for the “Smart Healthcare Technology Program”, further strengthening AI-driven healthcare innovations.

• Signed strategic business partnership agreement with iKooB for joint commercialization efforts.

2023 - 2022

• Successfully completed the TIPS 2nd Year Program & Startup Commercialization Support Project.

• Developed an AI-powered early detection & tracking platform for gastrointestinal cancer risk management.

• Conducted multi-hospital clinical studies with Seoul National University Hospital, Yonsei University Severance Hospital, and five other leading medical centers.

• Completed the CDW (Clinical Data Warehouse) AI System for Predicting Intradialytic Hypotension (IDH).

2021

• Developed and launched an AI-based early detection & tracking system for gastrointestinal cancer risk assessment.

• Selected for the TIPS Core Program, validating its potential for AI-driven clinical applications.

• Completed AI development for Acute Kidney Injury (AKI) prediction.

• Developed new AI-driven diagnostic models for early-stage cancer detection.

• Certified as a Venture Company.

2020 - 2019

• Completed a multi-tiered AI platform for Helicobacter pylori-associated stomach cancer risk assessment.

• Secured Seed investment from healthcare-focused venture capital.

• Selected for Korean government-backed startup acceleration programs, including:

  • Technology commercialization initiative for innovative SMEs.

  • Incheon National University’s AI healthcare R&D project.

• Recognized as the #1 innovation at the 2019 NEMIC (New England Medical Innovation Center) MedTech Bootcamp

Apex AI is committed to pioneering AI-driven gastrointestinal cancer diagnostics through continuous research and development. Our intellectual property portfolio includes multiple patents and software copyrights, solidifying our leadership in AI-powered medical imaging and predictive diagnostics.

Patents & Intellectual Property Filings

Software Copyrights & Certifications

About Apex AI

Apex AI is a pioneering artificial intelligence startup dedicated to early cancer detection and predictive diagnostics. Specializing in stomach and colorectal cancer, our AI-powered platform integrates cutting-edge machine learning models to revolutionize medical diagnostics and patient management. Currently, we are in the commercialization phase, collaborating with leading university hospitals and research institutions to bring AI-driven innovation to clinical practice.

Our Focus Areas

Apex AI is transforming gastrointestinal disease detection through AI-powered predictive analytics and real-time imaging technology.

Gastroenterology

• Stomach Cancer (Gastric Cancer)

  • AI-driven early detection and risk assessment system

  • Endoscopic AI analysis for precise identification of early-stage cancer

• Colorectal Cancer

  • AI-powered predictive system for colorectal cancer risk assessment

  • AI-assisted endoscopic imaging for early colorectal cancer detection

Bridging AI and Healthcare Innovation

Apex AI is at the forefront of medical AI innovation, bridging the gap between research and clinical applications. Our mission is to enhance early disease detection, improve patient outcomes, and streamline medical diagnostics through AI-powered solutions.

Apex AI's business model is structured into multiple phases, ensuring gradual market penetration, regulatory compliance, and long-term scalability.

Phase 1: New Medical Devices (Pre-Market Stage)

Apex AI is focused on early strategic partnerships and data integration before obtaining regulatory approvals.

Phase 2: Medical Device Approval & Expansion

Once regulatory approvals are obtained, Apex AI will shift towards direct clinical integration and cloud-based AI services.

Revolutionizing Gastrointestinal Cancer Diagnostics with AI

Apex AI has developed a cutting-edge AI-driven early detection system for stomach and colorectal cancer, leveraging over 1 million endoscopic imaging datasets to assist in the diagnosis of precancerous lesions, early-stage cancer, and advanced cancer.

How Apex AI’s Solution Works

• Divides the gastrointestinal tract into 14 anatomical regions for precise localization of abnormalities.

• Detects key gastrointestinal conditions, including:

  • Precancerous lesions: Atrophic gastritis, intestinal metaplasia.

  • Inflammatory conditions: Gastric ulcers, erosions, colitis.

  • Early and advanced cancers: Stomach and colorectal cancer.

• Seamlessly integrates with hospital imaging and endoscopic systems to enhance real-time clinical decision-making.

AI-Powered Cancer Risk Prediction & Diagnosis

Apex AI's system offers real-time image analysis, automated abnormality detection, and longitudinal disease tracking.

Core Features of AI-Assisted Endoscopic Diagnosis

• Patient Search & Data Integration

  • Connects with electronic medical records (EMR) for streamlined patient data access.

  • Allows historical comparisons of previous scans for tracking disease progression.

• Automated Endoscopic Image Interpretation

  • AI continuously analyzes real-time endoscopic footage, marking potential abnormalities.

  • Provides a comparative review of previous images to detect disease progression over time.

• Time-Based & Region-Based Disease Tracking

  • Allows doctors to monitor lesion evolution in specific locations within the gastrointestinal tract.

  • Enhances precision in monitoring high-risk patients over multiple screenings.

• High-Resolution Image Processing & Zoom Analysis

  • Enables doctors to zoom into detected lesions for a more detailed pathological assessment.

  • Reduces false positives by refining image interpretation.

Clinical Validation: AI vs. Human Accuracy

A retrospective clinical study comparing AI-assisted diagnosis with a panel of experienced doctors demonstrated superior accuracy in all key performance metrics.

Key Takeaways

• AI outperformed human doctors in accuracy, sensitivity, specificity, and precision.

• The AI model significantly reduces false negatives, ensuring high-risk lesions are detected early.

• AI-powered endoscopic analysis can improve diagnostic reliability and reduce misdiagnosis rates, leading to better patient outcomes.

Why AI is Critical for Early Detection in Gastrointestinal Cancer

• Early-stage stomach and colorectal cancers are often misdiagnosed or missed entirely due to subtle visual characteristics.

• AI enhances diagnostic confidence by improving detection accuracy, reducing human error, and supporting physicians in real-time.

• By adopting AI-assisted endoscopy, hospitals and clinics can drastically improve cancer survival rates worldwide.

Apex AI is at the forefront of this transformation, providing a next-generation AI diagnostic platform that will shape the future of gastrointestinal cancer detection.